Evolus, Inc. (NASDAQ:EOLS) Receives Average Rating of “Moderate Buy” from Analysts

Evolus, Inc. (NASDAQ:EOLS) has earned a consensus rating of “Moderate Buy” from the six analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $14.50.

A number of research analysts have weighed in on the company. Wall Street Zen raised Evolus from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings raised Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. Finally, BTIG Research reissued a “buy” rating and issued a $13.00 price target on shares of Evolus in a research note on Wednesday, June 17th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EOLS. Larson Financial Group LLC grew its position in Evolus by 136.6% during the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after acquiring an additional 2,837 shares during the period. Meeder Asset Management Inc. purchased a new position in shares of Evolus in the 4th quarter worth about $34,000. Wexford Capital LP acquired a new position in shares of Evolus in the 3rd quarter valued at about $37,000. California State Teachers Retirement System lifted its stake in shares of Evolus by 79.9% in the 2nd quarter. California State Teachers Retirement System now owns 5,455 shares of the company’s stock valued at $38,000 after purchasing an additional 2,423 shares in the last quarter. Finally, Legal & General Group Plc purchased a new stake in shares of Evolus during the 2nd quarter worth about $40,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Stock Down 0.8%

Shares of EOLS traded down $0.07 on Monday, hitting $8.32. 26,553 shares of the stock traded hands, compared to its average volume of 1,026,594. Evolus has a 1 year low of $3.86 and a 1 year high of $8.69. The stock’s 50 day moving average is $6.82 and its two-hundred day moving average is $5.77. The firm has a market capitalization of $549.67 million, a P/E ratio of -16.00 and a beta of 1.35.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.